Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

December 31, 2020

Conditions
Rectal CancerRectal Neoplasm
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV Days 1, 22 and 43

DRUG

Capecitabine

Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days

RADIATION

Radiation Therapy

Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)

Sponsors
All Listed Sponsors
collaborator

Hoosier Cancer Research Network

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Osama Rahma, MD

OTHER